Literature DB >> 18936692

Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.

Andrea Proctor Subhawong1, Ty Subhawong, Hind Nassar, Nina Kouprina, Shahnaz Begum, Russell Vang, William H Westra, Pedram Argani.   

Abstract

Basal-like carcinomas (BLCs) of the breast share discriminatory morphologic features with poorly differentiated high-risk human papilloma virus (HPV)-related squamous cell carcinomas of the oropharynx, penis, and vulva. Because HPV E7 protein inactivates the retinoblastoma (Rb) protein, diffuse p16 expression is a surrogate marker for these high-risk HPV-related carcinomas. HPV E6 protein also inactivates p53, further compromising the G1-S cell cycle checkpoint. The Rb/p16/p53 immunohistochemical profile of BLC of the breast has not been well characterized. Tissue microarrays containing 71 invasive ductal carcinomas (IDCs) of the breast were immunolabeled for p16, Rb, p53, and Ki-67. The cases included 4 distinct groups of IDCs having surrogate immunohistochemical profiles corresponding to categories defined by gene expression profiling (17 luminal A, 7 luminal B, 14 HER-2+, and 21 BLC), along with 12 unclassifiable triple negative carcinomas (UTNCs). Twenty-five of the 71 IDC were Rb negative/p16 diffuse positive (Rb-/p16+). These included 15 of 21 BLC and 9 of 12 UTNC, but only 1 of 14 HER-2 positive cases and none of the 17 luminal A or 7 luminal B cases (P<0.01, BLC or UTNC vs. others). Six of the Rb-/p16+ IDC also had a significant ductal carcinoma in situ component. The ductal carcinoma in situ in 4 of these 6 cases showed the same Rb-/p16+ phenotype as the associated IDC. BLC and UTNC had the highest Ki-67 indices of the 5 groups, even when matched for grade. The Rb-/p16+ phenotype and the Rb-/p16+/p53 overexpressing phenotype correlated with increased proliferation within the BLC group. In conclusion, BLC and UTNC, but not HER-2, luminal A, or luminal B carcinomas, frequently demonstrate an Rb-/p16+ phenotype, similar to the HPV-related squamous cell carcinomas that BLC resemble morphologically. This subset may represent a more homogenous group than BLC as defined currently.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18936692      PMCID: PMC2965595          DOI: 10.1097/PAS.0b013e31817f9790

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  46 in total

1.  Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Authors:  David J Dabbs; Mamatha Chivukula; Gloria Carter; Rohit Bhargava
Journal:  Mod Pathol       Date:  2006-08-25       Impact factor: 7.842

2.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

Review 3.  p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia.

Authors:  Alexandra N Kalof; Kumarasen Cooper
Journal:  Adv Anat Pathol       Date:  2006-07       Impact factor: 3.875

4.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

5.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Authors:  Mi-Jung Kim; Jae Y Ro; Sei-Hyun Ahn; Hak Hee Kim; Sung-Bae Kim; Gyungyub Gong
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

6.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 7.  p16 expression in the female genital tract and its value in diagnosis.

Authors:  Ciaran J O'Neill; W Glenn McCluggage
Journal:  Adv Anat Pathol       Date:  2006-01       Impact factor: 3.875

8.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Authors:  Bradley B Bryan; Stuart J Schnitt; Laura C Collins
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

Review 9.  Basal-like breast cancer and the BRCA1 phenotype.

Authors:  N C Turner; J S Reis-Filho
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

10.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.

Authors:  L G Fulford; D F Easton; J S Reis-Filho; A Sofronis; C E Gillett; S R Lakhani; A Hanby
Journal:  Histopathology       Date:  2006-07       Impact factor: 5.087

View more
  50 in total

1.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

2.  Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.

Authors:  Arvydas Laurinavicius; Aida Laurinaviciene; Valerijus Ostapenko; Darius Dasevicius; Sonata Jarmalaite; Juozas Lazutka
Journal:  Diagn Pathol       Date:  2012-03-16       Impact factor: 2.644

3.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

4.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

5.  Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Authors:  Zhe Jiang; Tao Deng; Robert Jones; Huiqin Li; Jason I Herschkowitz; Jeff C Liu; Victor J Weigman; Ming-Sound Tsao; Timothy F Lane; Charles M Perou; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

Review 6.  Male genital premalignant dermatoses.

Authors:  Oliver Kayes; Majid Shabbir; Suks Minhas
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

7.  RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.

Authors:  Agnieszka K Witkiewicz; Adam Ertel; Jeanne McFalls; Matias E Valsecchi; Gordon Schwartz; Erik S Knudsen
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

8.  Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes.

Authors:  Christopher M Heaphy; Andrea Proctor Subhawong; Amy L Gross; Yuko Konishi; Nina Kouprina; Pedram Argani; Kala Visvanathan; Alan K Meeker
Journal:  Mod Pathol       Date:  2010-11-05       Impact factor: 7.842

9.  Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.

Authors:  Charles Bechert; Jee-Yeon Kim; Trine Tramm; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-09-23       Impact factor: 4.064

10.  αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation.

Authors:  Vladimir Petrovic; Dmitry Malin; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2013-03-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.